A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).

被引：0
|
作者：
Swaminathan, Mahesh
Dinardo, Courtney Denton
Maiti, Abhishek
Pemmaraju, Naveen
Ohanian, Maro
Daver, Naval Guastad
Garcia-Manero, Guillermo
Issa, Ghayas C.
Borthakur, Gautam
Ravandi-Kashani, Farhad
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Valero, Yesid Alvarado
Jabbour, Elias
Short, Nicholas James
Wierda, William G.
Jain, Nitin
Kornblau, Steven Mitchell
Kantarjian, Hagop M.
Konopleva, Marina
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Bellaire, TX USA
[4] Albert Einstein Coll Med, Montefiore Med Ctr, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6549
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)
    Ghanem, Hady
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Faderl, Stefan
    Dellasala, Sara E.
    O'Brien, Susan M.
    Burger, Jan A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Quintas-Cardama, Alfonso
    Brandt, Mark
    Pierce, Sherry A.
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    [J]. BLOOD, 2012, 120 (21)
  • [22] Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.
    Ravandi, Farhad
    Abuasab, Tareq
    Valero, Yesid Alvarado
    Issa, Ghayas C.
    Islam, Rabiul
    Short, Nicholas James
    Yilmaz, Musa
    Jain, Nitin
    Masarova, Lucia
    Kornblau, Steven Mitchell
    Jabbour, Elias
    Pemmaraju, Naveen
    Bravo, Guillermo Montalban
    Pierce, Sherry
    Dinardo, Courtney Denton
    Kadia, Tapan M.
    Daver, Naval Guastad
    Konopleva, Marina
    Garcia-Manero, Guillermo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and PostHypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
    Rivera, Daniel
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Faderl, Stefan
    Sasaki, Koji
    Short, Nicholas J.
    Daver, Naval
    Di Nardo, Courtney D.
    Masarova, Lucia
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Borthakur, Gautham
    Al Azzawi, Hind
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Kantarjian, Hagop
    Ravandi, Farhad
    Alvarado, Yesid
    [J]. BLOOD, 2021, 138
  • [24] Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
    Senapati, Jayastu
    Almanza, Emmanuel Huante
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Faderl, Stefan
    Sasaki, Koji
    Short, Nicholas
    Daver, Naval
    DiNardo, Courtney D.
    Masarova, Lucia
    Ferrajoli, Alessandra
    Jabbour, Elias
    Borthakur, Gautam
    Al Azzawi, Hind
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Kantarjian, Hagop
    Ravandi, Farhad
    Alvarado, Yesid
    [J]. BLOOD, 2022, 140 : 9050 - 9053
  • [25] Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS)
    Yanada, M.
    Huang, X.
    O'Brien, S.
    Garcia-Manero, G.
    Ravandi, F.
    Borthakur, G.
    Issa, J.
    Giles, F.
    Kantarjian, H.
    Estey, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ghanem, Hady Antoine
    Ravandi, Farhad
    Faderl, Stefan
    Cortes, Jorge
    Reyes, Ardes S.
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Kantarjian, Hagop M.
    [J]. BLOOD, 2010, 116 (21) : 903 - 903
  • [27] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    [J]. BLOOD, 2021, 138
  • [28] Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Chen, Y.
    Kantarjian, H.
    Garcia-Manero, G.
    Estrov, Z.
    Konopleva, M.
    Jabbour, E.
    Kadia, T. M.
    Williams, E.
    George, S.
    Borthakur, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)
    Zeidner, Joshua F.
    Montiel-Esparza, Raul
    Knaus, Hanna A.
    Berglund, Sofia
    Zeidan, Amer M.
    McCurdy, Shannon R.
    Prince, Gabrielle T.
    Gondek, Lukasz P.
    Ghiaur, Gabriel
    Showel, Margaret M.
    DeZern, Amy E.
    Pratz, Keith W.
    Smith, B. Douglas
    Levis, Mark J.
    Foster, Matthew C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik W.
    Streicher, Howard
    Karp, Judith E.
    Luznik, Leo
    Gojo, Ivana
    [J]. BLOOD, 2016, 128 (22)
  • [30] Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study
    Kirschbaum, Mark
    Gojo, Ivana
    Goldberg, Stuart L.
    Kujawski, Lisa
    Atallah, Ehab
    Marks, Peter
    Di Gravio, Donna
    Pyle, Lisa
    Rizvi, Syed
    Issa, Jean-Pierre J.
    [J]. BLOOD, 2009, 114 (22) : 824 - 825
12345